Bedrijfsoverzicht
Fortress Biotech, Inc. is a biopharmaceutical enterprise dedicated to the development and commercialization of specialized biopharmaceutical products within the healthcare sector. The company specifically focuses on the biotechnology industry, targeting the dermatology market with products such as Emrosi, a minocycline hydrochloride extended-release capsule designed for the treatment of rosacea, as well as Qbrexza. As of the latest available data, the organization employs a workforce of 78 individuals and maintains a total market capitalization of $73.43 million. The entity reports an annual recurring revenue of $63.26 million, which positions it as a mid-cap player within the broader biotechnology landscape. These valuation and revenue metrics indicate that the company operates with a relatively small scale compared to large-cap pharmaceutical peers, suggesting a business model heavily reliant on the successful commercialization of its specific niche products rather than broad-market sales volume.
Financiële gezondheid
The financial performance of Fortress Biotech, Inc. is characterized by a revenue of $63.26 million for the trailing twelve months, which contrasts sharply with a net income of $-1,882,000 and an EBITDA of $-65,560,000. The significant divergence between the positive revenue figure and the negative net income and EBITDA reveals a cost structure where operating expenses and costs of goods sold substantially exceed gross profits, preventing the generation of bottom-line earnings. Furthermore, the company reports a free cash flow of $-47,286,376, indicating that current operational cash generation is insufficient to cover capital expenditures and working capital requirements without external financing. Regarding profitability margins, the gross margin stands at 48.1%, while the operating margin is negative at -29.8% and the profit margin is listed as 10.8%, a figure that appears inconsistent with the negative net income and requires contextual interpretation of the financial reporting period. On the balance sheet, Fortress holds $79.38 million in cash against $67.22 million in debt, resulting in a debt-to-equity ratio of 108.09 which suggests a leveraged financial position rather than a conservative one. Despite the debt load, the current ratio of 2.49 indicates strong short-term liquidity, meaning the company possesses more than double the current assets necessary to meet its immediate current liabilities. Additionally, the return on equity is -108.7% and the return on assets is -26.6%, metrics that collectively reveal that management has not yet achieved positive returns on the capital invested by shareholders or the asset base.
Waarderingsbeoordeling
Valuation multiples for Fortress Biotech, Inc. present a complex picture due to its lack of profitability, with the trailing P/E ratio and forward P/E ratio both listed as N/A. The absence of a positive trailing or forward P/E implies that traditional earnings-based valuation models are not applicable at this time, as the company is currently unprofitable. Instead, investors must rely on the price-to-book ratio of 7.59, which indicates that the market values the company at a significant premium relative to its book value, likely reflecting high expectations for future product approvals or successful commercialization. Alternative valuation metrics such as the price-to-sales ratio of 1.16 and an EV/EBITDA of -6.72 further suggest that the company is being valued based on sales potential rather than current earnings power or cash flow generation. The stock price has exhibited significant volatility, trading between a 52-week high of $14.64 and a 52-week low of $4.72, with the current market price sitting somewhere within this wide range. The company carries a beta of 1.45, which signifies that its share price is expected to be 45% more volatile than the broader market, a characteristic common among small-cap biotechnology firms.
Growth & Income
The company demonstrates a revenue growth rate of 6.3% year-over-year, while earnings growth is listed as N/A due to the lack of profitable earnings in the current period. Since earnings growth cannot be calculated against a profitable baseline, the revenue expansion serves as the primary indicator of business momentum, though the gap between revenue growth and the negative earnings trajectory highlights the ongoing investment phase of the company. Fortress Biotech, Inc. does not distribute dividends to shareholders, evidenced by a dividend yield and payout ratio of N/A, as the company retains all available earnings to fund research, development, and commercialization efforts rather than paying out income. Consequently, the overall growth and income profile is defined by capital appreciation potential driven by revenue expansion rather than income generation through dividends, requiring patience from investors waiting for the company to transition to profitability.